For the past month, Vir Biotechnology Inc. said it was working on ways to address the coronavirus epidemic that has killed 3,000 people since December. It made good on that promise Tuesday, inking a deal with Shanghai's WuXi Biologics. Financial terms of the development, manufacturing and commercialization collaboration centering on human monoclonal antibodies against the Covid-19 coronavirus were not disclosed by San Francisco-based Vir (NASDAQ: VIR). The deal emerges as the National Institute…